David Radice

Guul ten Velde1
Carin A Uyl-de Groot1
1Guul ten Velde
1Carin A Uyl-de Groot
Learn More
BACKGROUND In the last decade, a number of new treatment modalities have been developed for patients with small cell lung cancer (SCLC). The clinical effects are encouraging, but little is known about the costs and cost-effectiveness of new drugs. METHODS A Markov chain model has been developed to project patient outcomes and costs for patients with(More)
  • 1